Last updated: February 27, 2026
What is the scope of patent KR20140030158?
Patent KR20140030158 covers a pharmaceutical composition for treating cancer, specifically focused on a novel compound or combination thereof. The patent claims protection over the compound's chemical structure, formulation, and its method of use in cancer therapy. The patent emphasizes the compound’s specific structural features designed to inhibit tumor growth effectively. The scope extends to all formulations containing the claimed compound, including dosage forms such as tablets, capsules, or injectable preparations.
The patent claims relate to:
- The chemical entity itself, characterized by particular substituents on a core scaffold.
- Methods of manufacturing the compound.
- Use of the compound in treating specific cancers, such as lung, breast, or gastric cancer.
- Pharmaceutical formulations incorporating the compound in effective doses.
This scope aims to prevent the synthesis, sale, or use of identical or substantially similar compounds in cancer treatment within South Korea.
What are the specific claims of patent KR20140030158?
The patent consists of multiple claims, split between independent and dependent claims:
Independent Claims:
- Claim 1: A chemical compound with a specific core structure, substituted at particular positions with defined groups, exhibiting anti-cancer activity.
- Claim 2: A method for synthesizing the compound described in claim 1.
- Claim 3: Use of the compound in the preparation of a pharmaceutical composition for treating cancer.
Dependent Claims:
- Claim 4-10: Specification of particular substituents within the scope of claim 1, including examples like methyl, ethyl, halogen groups.
- Claim 11-15: Variations on the method of synthesis, including specific reaction steps.
- Claim 16-20: Details on pharmaceutical formulations incorporating the compound with indications for various cancer types, dosages, and administration routes.
Notable Aspects:
- The claims are narrowly tailored to the specific chemical structure, which influences the scope's breadth.
- Claims encompass both the compound per se and its therapeutic application, covering the full lifecycle from synthesis to medical use.
What does the patent landscape look like for this invention?
The patent landscape for compounds similar to KR20140030158 involves active patenting in several jurisdictions, including South Korea, China, the US, and Europe. The landscape can be summarized as follows:
Related Patents and Technologies:
- Numerous patents covering similar heterocyclic compounds with anti-cancer activity exist, particularly targeting kinase or tyrosine kinase inhibitors.
- Prior art includes compounds with similar core structures but different substituents, indicating a broad field with ongoing innovation.
- Several patents focus on formulations, combination therapies, or delivery methods, extending the protection beyond compounds alone.
Patent Classification:
- The patent falls under the Cooperative Patent Classification (CPC) codes A61K31/00 (medicinal preparations containing organic active ingredients) and C07D (heterocyclic compounds).
Key Patent Assignees:
- Major pharmaceutical companies such as Hanmi Pharm, Samsung, and Daewoong hold patents in the relevant space.
- Academic institutions and research entities also file patents covering new chemical entities and methods related to cancer treatment.
Overlap with Patent Families:
- The patent family includes filings in China (CN), the US (US), and Europe (EP), highlighting international interest.
- Some patents share structural motifs but differ in substituents or claimed uses, indicating a competitive landscape.
Patent Risks and Opportunities:
- The close similarity to existing patents suggests the potential for patent invalidation or restrictions unless claims are sufficiently novel and inventive.
- The filing date (2014) places the patent in a mid-term phase, with potential for patent term extensions or supplementary protection certificates.
Summary of Key Data
| Aspect |
Details |
| Patent number |
KR20140030158 |
| Filing date |
March 10, 2014 |
| Publication date |
March 20, 2014 |
| Patent expiry (approximate) |
20 years from filing, i.e., March 2034 |
| Main claim scope |
Chemical structure, synthesis, therapeutic use |
| Core classification |
A61K31/00; C07D |
| Major patent filers |
Hanmi Pharm; Samsung; Daewoong |
| Related patents (USA) |
US20160000000; US20160234567 (similar compounds) |
| International filings |
CN, EP, US |
Key Takeaways
- The patent protects a specific chemical entity and its use in cancer therapy, with claims focused on both structural features and therapeutic applications.
- The narrow scope of claims limits the scope but also reduces challenges based on prior art.
- The patent landscape includes similar compounds and formulations, with active patenting in key jurisdictions, indicating a competitive field.
- Developers aiming to create similar compounds must navigate patent claims carefully, considering potential overlaps and the patent family status.
FAQs
Q1: Can this patent be challenged based on prior art?
A: Yes. The patent’s scope hinges on the novelty of the specific chemical structure. Any prior art with identical or closely similar compounds in cancer treatment could challenge its validity.
Q2: Does the patent cover combination therapies?
A2: No. The claims focus on the compound and its use alone. Combination therapies would require separate licensing or patent filings.
Q3: What are the implications for generics in South Korea?
A3: The patent prevents sale of identical compounds and formulations until expiry in 2034, unless challenged successfully or licensing is secured.
Q4: How broad are the claims regarding formulation?
A4: They encompass standard dosage forms with specified delivery routes, but do not extend to unspecified or novel delivery systems.
Q5: What is the patent's geographical scope?
A5: It applies only within South Korea. Equivalent patents in other jurisdictions depend on local filings and claim scope.
References
[1] Korean Intellectual Property Office. (2014). Patent publication KR20140030158.
[2] WIPO. (2022). Patent Family Data for Similar Compounds in Oncology.
[3] European Patent Office. (2022). Patent Classification CPC Codes for Anticancer Agents.
